Palatin Technologies Inc
F:PTN

Watchlist Manager
Palatin Technologies Inc Logo
Palatin Technologies Inc
F:PTN
Watchlist
Price: 1.044 EUR 23.26% Market Closed
Market Cap: 20.4m EUR
Have any thoughts about
Palatin Technologies Inc?
Write Note

Palatin Technologies Inc
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Palatin Technologies Inc
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Palatin Technologies Inc
F:PTN
Other Current Assets
$228.4k
CAGR 3-Years
-57%
CAGR 5-Years
-18%
CAGR 10-Years
-8%
Abbvie Inc
NYSE:ABBV
Other Current Assets
$4.6B
CAGR 3-Years
2%
CAGR 5-Years
17%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Current Assets
$3.1B
CAGR 3-Years
7%
CAGR 5-Years
-2%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Current Assets
$449.2m
CAGR 3-Years
-1%
CAGR 5-Years
21%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Current Assets
$412m
CAGR 3-Years
-5%
CAGR 5-Years
13%
CAGR 10-Years
14%
No Stocks Found

Palatin Technologies Inc
Glance View

Market Cap
20.4m EUR
Industry
Biotechnology

Palatin Technologies Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to address unmet medical needs in various health conditions, particularly in women's health and sexual dysfunction. The company is primarily known for its lead product candidate, Vyleesi (bremelanotide injection), which was approved by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). This groundbreaking therapy offers a novel approach to a condition that has traditionally been underserved, highlighting Palatin’s commitment to improving quality of life for its patients. With a robust pipeline of other potential treatments, the company is positioning itself to be a significant player in the biotech sector. Investors will find Palatin appealing not only for its unique product offerings but also for its strategic partnerships and collaborations that enhance its research capabilities and market reach. The company has established relationships with key healthcare organizations, enabling it to conduct pivotal clinical trials and expand its product visibility. Additionally, leadership at Palatin utilizes a disciplined, value-investing approach, ensuring that resources are allocated wisely towards projects with solid scientific backing and commercial potential. As the company advances its portfolio, it aims to create long-term shareholder value while addressing critical areas of health, making it a compelling opportunity for those looking to invest in the future of biopharmaceutical innovations.

PTN Intrinsic Value
0.749 EUR
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Palatin Technologies Inc's Other Current Assets?
Other Current Assets
228.4k USD

Based on the financial report for Sep 30, 2024, Palatin Technologies Inc's Other Current Assets amounts to 228.4k USD.

What is Palatin Technologies Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
-8%

Over the last year, the Other Current Assets growth was -82%. The average annual Other Current Assets growth rates for Palatin Technologies Inc have been -57% over the past three years , -18% over the past five years , and -8% over the past ten years .

Back to Top